Diabetes and Sleep
Type 2 diabetes and sleep are tightly linked in both directions. Poor sleep impairs insulin sensitivity within days: a landmark study in JAMA Internal Medicine found that just 3 nights of 4-hour sleep reduced insulin sensitivity by 25%, equivalent to 10 to 20 kg of excess weight. Conversely, uncontrolled diabetes disrupts sleep through nocturia (frequent nighttime urination from hyperglycaemia), nocturnal hypoglycaemia (low blood sugar causing night sweats and waking), peripheral neuropathic pain, and restless leg syndrome.
For diabetic patients, blood sugar control before bed is a key sleep intervention. A small bedtime snack (15 to 20 g complex carbohydrate) may prevent nocturnal hypoglycaemia. Sleep apnoea is present in 40 to 70% of type 2 diabetic patients and treating it with CPAP improves glucose control independently of weight and medication changes.
Heart Disease and Sleep
Sleep apnoea is present in 40 to 80% of cardiac patients. Nocturnal episodes of apnoea cause acute cardiovascular stress through oxygen desaturation, sympathetic nervous system activation, and blood pressure surges that can trigger arrhythmias and acute coronary events. The SAVE trial demonstrated that CPAP treatment in cardiac patients with sleep apnoea significantly reduced cardiovascular events.
Heart failure patients experience a specific form of sleep-disordered breathing called Cheyne-Stokes respiration, characterised by a crescendo-decrescendo breathing pattern during sleep. This is not the same as obstructive sleep apnoea and requires different management. Insomnia in cardiac patients is associated with poorer outcomes and should be treated actively with CBT-I rather than hypnotics, which can worsen cardiac function.
Cancer-related fatigue and insomnia affect up to 80% of cancer patients during active treatment and up to 45% of survivors. Chemotherapy, radiation, corticosteroids, pain, anxiety, and cytokine-mediated inflammation all disrupt sleep. CBT-I adapted for cancer patients (CBT-I-C) has the strongest evidence base and is recommended before hypnotic medication.
Kidney Disease and Sleep
Chronic kidney disease (CKD) is one of the conditions most strongly associated with sleep disorders. Restless leg syndrome affects 20 to 70% of dialysis patients. Sleep apnoea prevalence exceeds 50% in end-stage renal disease. Uraemic toxin accumulation, metabolic acidosis, and anaemia all contribute to sleep disruption. Dialysis timing (night versus daytime dialysis) significantly affects sleep quality: studies show nocturnal home dialysis is associated with markedly better sleep and quality of life than conventional daytime dialysis.
Chronic Pain Conditions
Fibromyalgia, rheumatoid arthritis, osteoarthritis, and chronic low back pain all involve a bidirectional relationship with sleep disruption. Pain interrupts sleep; sleep deprivation lowers pain thresholds; lowered pain thresholds worsen pain; worsened pain further interrupts sleep. Breaking this cycle requires simultaneous treatment of both pain and sleep. Amitriptyline at low doses (10 to 25 mg at bedtime) treats both pain and sleep disruption in many chronic pain patients and is considered a first-line option by the British Pain Society.
- 1Diabetes: control blood glucose before bed, treat sleep apnoea, take late metformin in morning not evening
- 2Heart disease: screen for sleep apnoea, treat with CPAP, use CBT-I rather than hypnotics
- 3Cancer: ask oncologist about CBT-I-C referral, avoid daytime naps longer than 20 minutes
- 4Kidney disease: discuss dialysis timing with team if nocturnal dialysis option exists
- 5Chronic pain: explore low-dose amitriptyline at bedtime with prescriber, use CBT-I alongside pain management
- 6All conditions: discuss all medications with your team for timing optimisation and sleep-disruptive side effects